Abstract
Drug development can be a science of extrapolation if the use of a drug exposure-response relationship is embraced and implemented through mechanistically oriented pharmacokinetic (PK)-pharmacodynamic (PD) modeling analysis and clinical trial simulation. The traditional requirement of at least 2 adequate and well-controlled phase III studies by the US Food and Drug Administration for drug approval can be waived in certain situations, substantially reducing the resources and time. In this article, the authors introduce a real drug development case where the chance for this exemption was maximized by actively using PK-PD modeling followed by clinical trial simulation, resulting in faster and more economical introduction of a new dosage regimen to patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development.Annu Rev Pharmacol Toxicol. 2000;40:67–95.
Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry.Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications. Rockville, MD: Food and Drug Administration, 2003.
Sheiner LB. Learning versus confirming in clinical drug development.Clin Pharmacol Ther. 1997;61:275–291.
Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry.Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Rockville, MD: Food and Drug Administration, 1999.
The US Congress. The Federal Food, Drug, and Cosmetic Act, as amended in 1962. Pub. L. No. 87-781, 76 Stat. 780. 1962.
The US Congress. The Food and Drug Administration Modernization Act of 1997. Pub. L. No. 105-115, 111 Stat. 2295. 1997.
Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.Clin Pharmacol Ther. 2003;73:481–490.
Dower SK, Smith CA, Park LS. Human cytokine receptors.J Clin Immunol. 1990;10:289–299.
Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.J Rheumatol. 2001;28:1238–1244.
Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med. 2000;343:1586–1593.
Label for Enbrel® (etanercept). 2004.
Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers.Ann Pharmacother. 2000;34:161–164.
Lebsack ME, Hanna RK, Lange MA. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers.Pharmacotherapy. 1997;17:1181–1189.
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.Clin Pharmacol Ther. 2003;73:348–365.
Immunex. Data on File, Etanercept. 1999.
Bonate PL. Clinical trial simulation in drug development.Pharm Res. 2000;17:252–256.
Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.Clin Pharmacol Ther. 2000;68:568–577.
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. 50 mg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time-concentration profile with 25 mg twice weekly dosing.Clin Pharmacol Ther. 2002;71:90.
Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis Rheum. 2004;50:353–363.
Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.J Clin Pharmacol. 2005;45:246–256.
Amgen. FDA approves enbrel for once-weekly dosing: new dosing option offers convenience to patients while providing comparable efficacy and tolerability. Amgen press release. October 23, 2003.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: October 5, 2005
Rights and permissions
About this article
Cite this article
Lee, H., Yim, DS., Zhou, H. et al. Evidence of effectiveness: How much can we extrapolate from existing studies?. AAPS J 7, 47 (2005). https://doi.org/10.1208/aapsj070247
Received:
Accepted:
DOI: https://doi.org/10.1208/aapsj070247